In contrast to this structure-based over-expression, MYC dysregulation in response to constitutive growth factor signaling is commonly encountered in many tumor types with Ras mutations and in most sporadic colo-rectal cancers owing to acquired mutations of the APC tumor suppressor that unleash constitutive β-catenin signaling [4,11,12]. Here, MYC is linked to neoplasm.